Myopia progression in children research hub

A randomized, double-blind, placebo-controlled dose-finding study of 0.05%, 0.025%, 0.01% and 0.005% atropine eye drops to inhibit myopia progression in children in a European population

This study is looking at different strengths of atropine eye drops to slow down short-sightedness in children. It compares them to drops with no medicine (placebo) to see which strength works best and is safest over 12 months.